---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-093979"
form_type: "8-K"
ticker: "NTRA"
cik: "0001604821"
company_name: "Natera, Inc."
filed_at: "2021-07-20T23:59:59+00:00"
generated_at: "2026-06-30T04:06:53.384212+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Natera reports preliminary Q2 revenue ~$138-141M (+60% YoY); Women's Health cash flow breakeven

## Summary
- Total revenue expected $138-141M vs $86.5M in Q2 2020, a record ~60% YoY growth.
- Product revenue $135-137M, up ~70% YoY from $80.4M; processed ~370,000 tests (+58%).
- Women's Health business achieved cash flow breakeven for the first time in Q2 2021.
- Loss from operations widened to $113-117M from $51.7M due to higher R&D and SG&A costs.
- On May 11, 2021 entered a development/option deal: paid $10M; option to buy assets for $290M.

## SEC filing metadata
- accession: 0001104659-21-093979
- form_type: 8-K
- ticker: NTRA
- cik: 0001604821
- company_name: Natera, Inc.
- filed_at: 2021-07-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604821/000110465921093979/0001104659-21-093979-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604821/000110465921093979/tm2115665d4_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-093979
- JSON: https://secwatch.observer/filing/0001104659-21-093979.json
- Plain text: https://secwatch.observer/filing/0001104659-21-093979.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.